Kyalin Biosciences' Acquisition

Kyalin Biosciences was acquired by Retrophin on December 12, 2013.

Kyalin Biosciences develops therapies targeting the core symptoms of autism and related conditions. Kyalin is currently developing a highly optimized intranasal delivery form of carbetocin, the latter…

Articles about Kyalin Biosciences' Acquisition: